Inactive Instrument

Imago BioSciences, Inc.

Equities

IMGO

US45250K1079

Biotechnology & Medical Research

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Imago BioSciences, Inc. Announces Board Changes CI
Merck & Company Concludes Cash Tender Offer to Acquire Imago BioSciences MT
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Composite Index CI
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from S&P Global BMI Index CI
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from S&P TMI Index CI
Merck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc.. CI
Insider Sell: Imago Biosciences MT
Insider Sell: Imago Biosciences MT
Insider Sell: Imago Biosciences MT
Imago BioSciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis CI
Insider Sell: Imago Biosciences MT
Insider Sell: Imago Biosciences MT
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Biotechnology Index CI
Imago BioSciences Reports 'Positive' Mid-Stage Results in Thrombocythemia Trial MT
Imago BioSciences, Inc. Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022 CI
Merck Begins Tender Offer to Acquire Imago BioSciences MT
Iimago Biosciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia CI
North American Morning Briefing : China Reopening -2- DJ
Stifel Nicolaus Downgrades Imago BioSciences to Hold From Buy, Adjusts Price Target to $36 From $35 MT
PUMP / DUMP #52 : This week's gainers and losers Our Logo
Jefferies Downgrades Imago BioSciences to Hold From Buy, Adjusts Price Target to $36 From $35 MT
Cowen Downgrades Imago BioSciences to Market Perform From Outperform, Price Target is $36 MT
HC Wainwright Downgrades Imago BioSciences to Neutral From Buy, Lifts Price Target to $36 From $35 MT
North American Morning Briefing : Stock Gains Seen -2- DJ
Merck & Co. To Buy Bone Marrow Disease-focused Imago BioSciences For $1.4 Billion MT
Chart Imago BioSciences, Inc.
More charts
Imago BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing small molecule product candidates that target lysine-specific demethylase 1 (LSD1), an enzyme that plays a central role in the production of blood cells in the bone marrow. It focuses on providing treatment for patients with cancer and bone marrow diseases. The Company's lead product candidate is bomedemstat, which is developed for the treatment of myeloproliferative neoplasms (MPNs), a chronic cancer of the bone marrow. The Company's product candidate, bomedemstat, is in Phase II clinical trial for the treatment of essential thrombocythemia (ET). The Company also develops bomedemstat and other LSD1-targeting product candidates for additional indications in areas of unmet medical need. It tests bomedemstat in mouse models of MPNs as a single agent.
More about the company
  1. Stock
  2. Equities
  3. Stock Imago BioSciences, Inc. - Nasdaq
  4. News Imago BioSciences, Inc.
  5. Wedbush Downgrades Imago BioSciences to Neutral From Outperform on Heels of Announced Sale to Merck, Adjusts PT to $36 From $25